Literature DB >> 19955832

Insights into the pathogenesis and genetic background of patency of the ductus arteriosus.

Regina Bökenkamp1, Marco C DeRuiter, Conny van Munsteren, Adriana C Gittenberger-de Groot.   

Abstract

The unique differentiation program of the ductus arteriosus (DA) is essential for its specific task during fetal life and for the adapting circulation after birth. Phenotypic changes occur in the DA during the normal maturation and definitive closure. Morphological abnormalities of the vessel wall characterize the persistent DA (PDA) in older children. Here, we give an overview of the animal models of DA regulation and remodeling. Genetic research has identified the cause of syndromic forms of PDA, such as the TFAP2B mutations in Char syndrome. Genes that interfere with the remodeling of vascular smooth muscle cells (VSMCs) of the ductal media are affected in virtually all of these anomalies. Therefore, the pivotal regulatory role of VSMCs is emphasized. A better understanding of the genetic background of this developmental process may help develop new strategies to manipulate the DA in premature infants, neonates with duct-dependent anomalies, and patients with syndromic and non-syndromic PDA.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19955832     DOI: 10.1159/000262481

Source DB:  PubMed          Journal:  Neonatology        ISSN: 1661-7800            Impact factor:   4.035


  31 in total

Review 1.  Novel drug targets for ductus arteriosus manipulation: Looking beyond prostaglandins.

Authors:  Elaine L Shelton; Gautam K Singh; Colin G Nichols
Journal:  Semin Perinatol       Date:  2018-05-10       Impact factor: 3.300

2.  Familial nonsyndromic patent ductus arteriosus caused by mutations in TFAP2B.

Authors:  Yi-Wei Chen; Wu Zhao; Zhi-Fang Zhang; Qihua Fu; Jie Shen; Zhen Zhang; Wei Ji; Jian Wang; Fen Li
Journal:  Pediatr Cardiol       Date:  2011-06-04       Impact factor: 1.655

Review 3.  Genetics of the patent ductus arteriosus (PDA) and pharmacogenetics of PDA treatment.

Authors:  Tamorah R Lewis; Elaine L Shelton; Sara L Van Driest; Prince J Kannankeril; Jeff Reese
Journal:  Semin Fetal Neonatal Med       Date:  2018-02-24       Impact factor: 3.926

Review 4.  Transcriptional profiling of the ductus arteriosus: Comparison of rodent microarrays and human RNA sequencing.

Authors:  Michael T Yarboro; Matthew D Durbin; Jennifer L Herington; Elaine L Shelton; Tao Zhang; Cris G Ebby; Jason Z Stoller; Ronald I Clyman; Jeff Reese
Journal:  Semin Perinatol       Date:  2018-05-10       Impact factor: 3.300

5.  Identification of differentially regulated genes in human patent ductus arteriosus.

Authors:  Pratik Parikh; Haiqing Bai; Michael F Swartz; George M Alfieris; David A Dean
Journal:  Exp Biol Med (Maywood)       Date:  2016-07-28

Review 6.  Patent Ductus Arteriosus of the Preterm Infant.

Authors:  Shannon E G Hamrick; Hannes Sallmon; Allison T Rose; Diego Porras; Elaine L Shelton; Jeff Reese; Georg Hansmann
Journal:  Pediatrics       Date:  2020-11       Impact factor: 7.124

7.  BMP9 and BMP10 are necessary for proper closure of the ductus arteriosus.

Authors:  Sandrine Levet; Marie Ouarné; Delphine Ciais; Charles Coutton; Mariela Subileau; Christine Mallet; Nicolas Ricard; Marie Bidart; Thierry Debillon; Francesca Faravelli; Caroline Rooryck; Jean-Jacques Feige; Emmanuelle Tillet; Sabine Bailly
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-08       Impact factor: 11.205

Review 8.  Cardiac Embryology and Molecular Mechanisms of Congenital Heart Disease: A Primer for Anesthesiologists.

Authors:  Benjamin Kloesel; James A DiNardo; Simon C Body
Journal:  Anesth Analg       Date:  2016-09       Impact factor: 5.108

Review 9.  Role of endothelin in uteroplacental circulation and fetal vascular function.

Authors:  Alexandra Paradis; Lubo Zhang
Journal:  Curr Vasc Pharmacol       Date:  2013-09       Impact factor: 2.719

Review 10.  Clinical pharmacology of indomethacin in preterm infants: implications in patent ductus arteriosus closure.

Authors:  Gian Maria Pacifici
Journal:  Paediatr Drugs       Date:  2013-10       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.